about us

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing novel cancer vaccine immunotherapies for the treatment of brain, ovarian and other solid tumors. Our product candidates are based on a next-generation dendritic cell (DC) vaccine technology that stimulates a potent immune response to antigens associated with both cancer cells and cancer stem cells (CSCs), which are primary drivers of tumor growth and recurrence. Advanced manufacturing allows the production and storage of multiple vaccine doses from a single process, offering notable advantages over existing manufacturing methods in terms of cost-effectiveness, efficiency and convenience.

About Us Collage

Our lead product candidate, ICT-107, has completed a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial in patients with newly diagnosed glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. Results of a phase I study of ICT-107 showed prolonged survival compared with historical controls and minimal side effects. A top-line data read-out from the phase II study was reported in December 2013, and updated data from the phase II study were reported at the American Society for Clinical Oncology (ASCO) annual meeting in June 2014 and at the Society for Neuro-Oncology (SNO) meeting in November 2014.

In addition to ICT-107, we are developing two other DC vaccines.

ICT-121 is a DC vaccine that targets CD133, an antigen commonly associated with CSCs. We are conducting a 20-patient phase I clinical trial in patients with recurrent glioblastoma.

ICT-140 is a DC vaccine that targets seven different antigens associated with ovarian cancer, including ones expressed by CSCs. We plan to conduct an exploratory phase II clinical trial in ovarian cancer. 

Through a licensing agreement with the California Institute of Technology (Caltech), we have exclusive rights to novel technology for the development of certain antigen specific T cell immunotherapies for the treatment of cancer. The technology originated from the labs of David Baltimore, Ph.D., Nobel Laureate and President Emeritus at Caltech, and utilizes the patient’s own hematopoietic stem cells to create antigen-specific killer T cells to treat cancer. We plan to utilize this technology to expand and complement our dendritic cell-based cancer vaccine platform, with the goal of developing new immunotherapies that kill cancer cells in a highly directed and specific manner and that can function as monotherapies or in combination therapy approaches.

ImmunoCellular’s goal is to become an industry-leading, independent, commercial-stage cancer immunotherapy company. We have a development pipeline of what we believe are therapeutically important, commercially attractive assets, and a highly productive, proprietary cancer vaccine platform that has the potential to transform the treatment of cancer, bring therapeutic benefit to patients and hope to their families, and create value for our stakeholders.

Copyright 2015 by Immunocellular Therapeutics, Ltd.
All Rights Reserved